PMID: 9449014Feb 4, 1998Paper

Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy

Drug and Alcohol Dependence
David A Gorelick

Abstract

Existing pharmacodynamic approaches to cocaine abuse treatment have not been widely successful. An alternative, pharmacokinetic, approach is to enhance cocaine metabolism by administration of butyrylcholinesterase (BChE), a major cocaine-metabolizing enzyme in primates. Initial studies in rodents suggest that BChE pretreatment can substantially reduce the acute physiological and behavioral effects of cocaine, at enzyme doses that themselves have no behavioral or toxic effects. A single enzyme injection may increase plasma BChE activity for several days, suggesting that exogenous administration may be practical. BChE treatment may also produce a favorable pattern of cocaine metabolites. Further research is needed to evaluate the long-term effects of BChE administration.

References

May 1, 1977·Life Sciences·D J StewartW Kalow
Oct 1, 1975·The Journal of Pharmacy and Pharmacology·A L MisraS J Mulé
May 1, 1979·Anesthesia and Analgesia·P JatlowR Byck
May 1, 1977·Canadian Anaesthetists' Society Journal·K L SchollerH G Benkmann
Jan 1, 1976·Acta Anaesthesiologica Scandinavica·J Stovner, K Stadskleiv
May 1, 1992·Immunopharmacology·O BagasraP Whittle
Mar 1, 1992·Annals of Emergency Medicine·R S HoffmanL R Goldfrank
May 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·L RothS M Roberts
Jan 1, 1991·Neuroscience and Biobehavioral Reviews·B P DoctorY Ashani
Jan 1, 1990·Life Sciences·J A Madden, R H Powers
Sep 1, 1989·Canadian Journal of Physiology and Pharmacology·T Inaba
Jan 15, 1989·Annals of Internal Medicine·P Devenyi
Aug 1, 1995·Pharmacology, Biochemistry, and Behavior·R F Genovese, B P Doctor
Dec 1, 1993·Pharmacology, Biochemistry, and Behavior·R BrandeisY Ashani
Jul 1, 1993·Progress in Neurobiology·J MassouliéF M Vallette
Mar 26, 1993·Science·D W LandryT M Georgiadis
Oct 1, 1996·Nature Medicine·B S FoxT J Briner

❮ Previous
Next ❯

Citations

Nov 9, 2007·Journal of Computer-aided Molecular Design·Fang Zheng, Chang-Guo Zhan
Dec 21, 2000·Current Psychiatry Reports·P C GottschalkT R Kosten
Mar 18, 2008·Journal of the American Chemical Society·Yongmei PanChang-Guo Zhan
Aug 20, 2008·Journal of the American Chemical Society·Fang ZhengChang-Guo Zhan
Aug 1, 2009·Journal of the American Chemical Society·Junjun LiuChang-Guo Zhan
Jul 21, 2006·The Journal of Physical Chemistry. B·Adel HamzaChang-Guo Zhan
Aug 19, 2007·The Journal of Physical Chemistry. B·Haiting LuChang-Guo Zhan
May 1, 2009·The Journal of Physical Chemistry. B·Yongmei PanChang-Guo Zhan
Jan 18, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stephen BrimijoinMarilyn E Carroll
May 4, 2010·Protein Engineering, Design & Selection : PEDS·Diwahar NarasimhanRoger K Sunahara
Jul 2, 2005·Journal of Psychiatric Practice·C J Welsh, J Liberto
Dec 1, 2007·Journal of Addiction Medicine·Rinah T YamamotoMarc J Kaufman
Nov 7, 2008·Molecular Pharmacology·Daquan GaoChang-Guo Zhan
Jul 6, 2004·Drugs·David A GorelickZheng-Xiong Xi
Mar 22, 2014·Human Gene Therapy. Clinical Development·Martin J HicksRonald G Crystal
Feb 4, 2012·Future Medicinal Chemistry·Stephen Brimijoin, Yang Gao
Feb 4, 2012·Future Medicinal Chemistry·Charles W Schindler, Steven R Goldberg
Feb 4, 2012·Future Medicinal Chemistry·David A Gorelick
Feb 4, 2012·Future Medicinal Chemistry·Diwahar NarasimhanRoger K Sunahara
Jul 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·M Rocio A CarreraKim D Janda
Nov 9, 2005·Proceedings of the National Academy of Sciences of the United States of America·Yongmei PanChang-Guo Zhan
Feb 27, 2003·Journal of the American Chemical Society·Chang-Guo ZhanDonald W Landry
Mar 1, 2008·Expert Review of Clinical Pharmacology·David A Gorelick
Jan 1, 2009·Expert Review of Clinical Pharmacology·Chang-Guo Zhan
Dec 25, 2009·Journal of Enzyme Inhibition and Medicinal Chemistry·Shyh-Ying ChiouGialih Lin
Jun 15, 2005·Expert Opinion on Biological Therapy·Tobin J DickersonKim D Janda
Jan 4, 2001·Substance Use & Misuse·B K Boyarsky, E F McCance-Katz
Oct 17, 2014·The American Journal of Drug and Alcohol Abuse·Paula AskalskySandra D Comer
May 10, 2005·Journal of Computational Chemistry·Chang-Guo ZhanDonald W Landry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.